SCM
IKT icon

Stonepine Capital Management’s Inhibikase Therapeutics IKT Stock Holding History

Stonepine Capital Management’s Portfolio IKT Stock Details IKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$804K Sell
396,179
-561,023
-59% -$1M 0.45% 51
2026
Q1 		$1.61M Sell
957,202
-1,390,945
-59% -$2.47M 0.64% 26
2025
Q4 		$4.81M Buy
2,348,147
+1,613,128
+219% +$2.57M 3.51% 5
2025
Q3 		$1.19M Buy
735,019
+1,226
+0.2% +$2.12K 0.97% 23
2025
Q2 		$1.43M Sell
733,793
-181,180
-20% -$355K 1.4% 17
2025
Q1 		$2M Sell
914,973
-217,415
-19% -$546K 1.95% 18
2024
Q4 		$3.68M Buy
+1,132,388
New +$2.82M 2.97% 12

Other funds holding IKT

SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Stonepine Capital Management's IKT Position: Q2 2026 in Review

Stonepine Capital Management reduced its Inhibikase Therapeutics (IKT) stake by 59% in Q2 2026, selling an estimated $1M and leaving 396,179 shares worth $804K. The position accounts for 0.45% of the portfolio, ranked #51.

Stonepine Capital Management first reported a position in IKT in Q4 2024 and has held it in 7 quarters since. The position peaked at $4.81M in Q4 2025. 106 funds tracked by Wall St. Rank hold IKT as of Q2 2026.

  • Stonepine Capital Management held 396,179 shares of Inhibikase Therapeutics worth $804K as of Q2 2026.
  • Stonepine Capital Management sold 561,023 Inhibikase Therapeutics shares in Q2 2026, an estimated $1M.
  • Inhibikase Therapeutics made up 0.45% of Stonepine Capital Management's portfolio in Q2 2026, its #51 holding.
  • Stonepine Capital Management first reported a position in Inhibikase Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • Stonepine Capital Management's Inhibikase Therapeutics position peaked at $4.81M in Q4 2025.
  • 106 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q2 2026.

Based on Stonepine Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.